Publicacións nas que colabora con Rebeca Fraga Iriso (4)

2019

  1. Letter: double‐dose intensification – a quick way to reverse antibody formation and loss of response in patients treated with adalimumab

    Alimentary Pharmacology & Therapeutics, Vol. 49, Núm. 6, pp. 821-822

2016

  1. P521. Anti-TNF serum level and clinical, radiological or endoscopical response in luminal and perianal Crohn’s disease: results of the OPTIMIZA study

    Journal of Crohn's and Colitis, Vol. 10, Núm. suppl 1, pp. S364.1-S364

2015

  1. P526. Impact of postinduction infliximab trough level and disease activity on primary response in Crohn's Disease

    Journal of Crohn's and Colitis, Vol. 9, Núm. suppl 1, pp. S342-S343

2014

  1. Drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn disease

    Gastroenterology, Vol. 146, Núm. Suppl. 1, pp. 247